



Supplementary Materials: Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?

Yoann Cazaubon, Yohann Talineau, Catherine Feliu, Céline Konecki, Jennifer Russello, Olivier Mathieu, and Zoubir Djerada




Figure S1. Comparison between simulated concentration profile from our final model versus median (min-max) value of mitotane at 84 days of therapy from study of Kerkhofs et al. [34].

Model	Number of Covariates	-2LL	BIC	ΔΒΙΟ	RSE of Parameters
Basic model (1 cmt)	0	3005	3027		< 30%
Tg on Cl (1cmt)	1	2994	3019	-8	< 30%
Tg and HDL on Cl (1cmt)	2	2988	3015	-12	< 30%
Tg, HDL and Lcat2 on Cl (1cmt)	3	2960	2093	-34	< 30%
Basic model with TVC Equation 6	0	2999	3030	-3	>1000%
Arshad et al.[16]	1	3026	3051	+24	< 30%

Abbreviations are as follows: $-2LL = -2 \times loglikelihood; \Delta BIC = BIC (model step) - BIC (basic model); RSE, Relative standard error; BIC, Bayesian information criterion; lcat2, latent covariate; Tg, triglyceride; TVC, Time-varying clearance.$

Equation S1. Summary of equations to model a time-varying clearance.

$$Cl_{linear} = Cl_{initial} + k_{out} \times TIME \tag{1}$$

$$Cl_{exp} = Cl_{initial} \times e^{k_{out} \times TIME}$$
⁽²⁾

$$Cl_{initial\ exp} = Cl_{initial} + Cl_{ss} \times e^{k_{out} \times TIME}$$
⁽³⁾

$$Cl_{concave} = Cl_{initial} + Cl_{ss} \times (1 - e^{-k_{out} \times TIME})$$
⁽⁴⁾

$$Cl_{Emax} = Cl_{initial} + Cl_{ss} \times \left(\frac{TIME^{\gamma}}{TIME^{\gamma} + T50^{\gamma}}\right)$$
(5)

$$Cl_{pheno1} = Cl_{ss} - (Cl_{ss} - Cl_{initial}) \times \left(\frac{T12}{T12 + TIME}\right)$$
 (6)

$$Cl_{pheno2} = Cl_{ss} - (Cl_{ss} - Cl_{initial}) \times e^{\left(\frac{-TIME}{T12}\right)}$$
(7)

$$Cl_{mecha} = Cl \times ddt_{Enz} \left\{ = K_{enz} - K_{enz} \times \left(1 - \frac{Cc}{Cc + IC_{50}}\right) \times Enz \right\}$$
 (8)

Abbreviations are as follows: $Cl_{initial}$ clearance at time = 0, Clss induced clearance, k_{out} rate constant for the change in clearance rate. γ gamma (shape factor), TIME time after first administration, T50 time at which clearance of the Cl_{Emax} model reaches 50% of its final value, T12 time scale at which clearance change, Cc mitotane plasma concentration, K_{enz} .